Is the prolonged action of levosimendan of relevance with our patient length of stay and pathologies?

Does the length of action of levosimendan affect ICU patients’ length of stay and outcomes? In this ‘Peer-to-peer clinical Xchange’ session held on the Orion booth at ISICEM 2018, Dr Antoine Herpain from Erasme University Hospital, Université Libre de Bruxelles reviews the pharmacological profile of levosimendan and patient outcomes following treatment of cardiogenic shock, cardiac surgery, septic cardiomyopathy and stress cardiomyopathy (Takotsubo).


ISICEM 2018 resources

Videos (5)
Login/ Register Maximise Minimise